Aveo Oncology ’s tivozanib enters Phase II part of TiNivo trial for RCC
US-based biopharmaceutical firm Aveo Oncology ’s oral drug candidate tivozanib has advanced into the Phase II part of the Phase I/II TiNivo clinical trial to treat advanced renal cell carcinoma (RCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Oral Cancer | Renal Cell Carcinoma